Skip to main content
Caplight Logo









Sorriso Pharmaceuticals

Sorriso Pharmaceuticals

Private
Sandy, UtahHealthcare & Life Scienceshttps://sorrisopharma.com/

Last Round

Series A

Dec 22, 2021

Est. Valuation

$50M

Total Funding Raised

$31M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sorriso Pharmaceuticals is a biopharmaceutical company developing oral disease-modifying antibodies for the treatment of inflammatory diseases such as Crohn's disease and ulcerative colitis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysingle-domain antibodyoral biologicsinflammatory bowel diseaseIBDnanobodydrug discoverygut-restricted therapyCrohn's diseaseulcerative colitisbiopharmaclinical-stage biotechbispecific antibodyanti-TNFdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sorriso Pharmaceuticals Comparables

Compare Sorriso Pharmaceuticals with similar companies based on industry and business-model similarity.

Sorriso Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Caldera Therapeutics
88%
GAT Biosciences S.L.
86%
Mage Biologics Inc.
84%

Sorriso Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 22, 2021

Sorriso Pharmaceuticals Investors

Notable investors and investment history

Sorriso Pharmaceuticals investors
InvestorRounds
A. M. Pappas & AssociatesSeries A
New Enterprise AssociatesSeries A
Lundbeckfonden BioCapitalSeries A
Arix BioscienceSeries A
Biovision VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 34% MoM, reaching 1.8K.

  • Apr 18, 2026

    Monthly visitors increased 42% MoM.

Sorriso Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Sorriso Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sorriso Pharmaceuticals's valuation, stock price, and market status.

Is Sorriso Pharmaceuticals a public or private company?

Sorriso Pharmaceuticals is a private company.

What is the current stock price of Sorriso Pharmaceuticals?

Sorriso Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Sorriso Pharmaceuticals worth (valuation)?

Sorriso Pharmaceuticals's valuation is estimated at $50.0M based on funding round data.

Can I buy Sorriso Pharmaceuticals stock?

Sorriso Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sorriso Pharmaceuticals's last funding round?

Sorriso Pharmaceuticals's most recent funding round was Series A on December 22, 2021.

Who are the main investors in Sorriso Pharmaceuticals?

Key investors in Sorriso Pharmaceuticals include New Enterprise Associates (NEA), Arix Bioscience.

Will Sorriso Pharmaceuticals IPO soon?

No public IPO plans have been announced for Sorriso Pharmaceuticals.

How can I track Sorriso Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sorriso Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSandy, Utah
Employee Range11
Year Founded2020
Last FundingDec 22, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?